Codabakalner not checked

Spinogenix · SPG601

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD)
Main trialPhase 2/3
“This is a Study to Investigate the Effects and Safety of Codabakalner for the Treatment of Fragile X Syndrome in Male Participants and Adult Participants with Autism Spectrum Disorders”In the company’s words, NCT07439510 on ClinicalTrials.gov
Other names
SPG601

Other drugs for Fragile X Syndrome (FXS)

All 7 drugs for Fragile X Syndrome (FXS)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2/3Not yet recruiting 1 Feb 2030 A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADS
Phase 2Completed 31 Dec 2024 Study of SPG601 in Adult Men With Fragile X Syndrome
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Codabakalner

Following is part of Solo: you see every change to Codabakalner the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in